IP Library › Granted Patent US 7,056,887
Granted Patent B2
US 7,056,887 · App. 10/322,839 · Granted Jun 6, 2006

Treatment of acute coronary syndrome with GLP-1

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,056,887
App. No.
10/322,839
Granted
Jun 6, 2006
Kind
B2
Abstract

The invention relates to methods for treating a patient suffering from acute coronary syndrome, but who is not suffering from a Q-wave myocardial infarction, comprising administration of a therapeutically effective amount of an exendin-4 molecule. The exendin-4 can be self-administered, and can be administered in one or more doses, as needed, on an intermittent or continuous basis, to optimize metabolism in cardiac tissue and to prevent cardiac damage associated with ischemia.

Claims (12)

1. A method of treating a patient suffering from acute coronary syndrome, comprising administering to the patient a therapeutically effective amount of an exendin-4.

2. The method of claim 1 , wherein the exendin is administered in at least one dose.

3. The method of claim 1 , wherein the exendin is administered continuously.

4. The method of claim 1 , wherein glucose, a potassium salt, or a combination thereof, is co-administered with the exendin.

5. The method of claim 1 , wherein said patient has a condition selected from the group consisting of unstable angina, non-Q-wave cardiac necrosis, Q-wave myocardial infarction, acute myocardial infarction, ischemic heart disease, and stable angina.

6. The method of claim 1 , wherein the patient has a blood troponin I level of no more than 0.4 ng/ml.

7. The method of claim 1 , wherein the patient has a blood troponin T level of no more than 0.1 ng/ml.

8. The method of claim 1 , wherein the patient does not have elevated blood creatine kinase.

9. The method of claim 1 , wherein the patient does not have ST-segment elevation.

10. The method of claim 1 , wherein the patient does not exhibit a pathological Q-wave.

11. The method according to claim 1 , wherein said patient exhibits one or more of the following symptoms: chest pain greater than 15 minutes in duration, chest pain at rest, chest pain following minimal exertion that is poorly responsive to sublingual nitrates.

12. The method according to claim 1 , wherein said patient self-administers the exendin.

Assignments (1)
RELEASE OF SECURITY INTEREST Recorded Oct 1, 2012
From: ELI LILLY AND COMPANY
To: AMYLIN PHARMACEUTICALS, INC.
Reel/Frame 029057/0342 →